<DOC>
	<DOCNO>NCT00002618</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Giving drug different dos may kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy various combination drug treat pediatric patient advanced-stage large cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare event free survival child advance stage large cell lymphoma treat modified APO ( doxorubicin/prednisone/vincristine/mercaptopurine ) without intermediate-dose methotrexate/high dose cytarabine maintenance therapy follow induction therapy APO . II . Characterize immunophenotypic morphologic correlate pediatric large cell lymphoma . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm , except CNS disease . These patient assign arm II receive whole brain irradiation Regimen B . Arm I : Induction ( Modified APO ) : Patients receive vincristine IV day 1 , 8 , 15 , 22 , 29 , doxorubicin IV 15 minute day 1 22 , prednisone three time day day 1-28 , methotrexate intrathecally ( IT ) day 1 , 8 , 22 . Patients complete remission day 43 proceed maintenance , partial remission undergo biopsy proceed maintenance , residual disease receive radiotherapy regimen A concurrently maintenance . Maintenance ( day 1 day 43 Induction ) : Courses intermediate dose methotrexate/leucovorin calcium high dose cytarabine ( ID MTX/CF/HD ARA-C ) modify APO alternate every 3 week . Patients receive total 15 course ( 8 ID MTX/CF/HD ARA-C 7 Modified APO ) . ID MTX/CF/HD ARA-C : Patients receive methotrexate IV 24 hour day 1 , leucovorin calcium IV orally every 6 hour day 2 3 , cytarabine IV 48 hour day 2 4 , methotrexate IT day 1 course 1 , 3 , 5 . Filgrastim ( G-CSF ) administer begin day 5 continue blood count recover . Modified APO : Patients receive vincristine IV day 1 , oral mercaptopurine day 1-5 , doxorubicin IV 15 minute day 1 , oral prednisone three time day day 1-5 . Arm II : Induction : Patients receive treatment arm I except patient CNS disease also receive methotrexate IT day 15 , 29 , 36 . Maintenance ( day 1 day 43 Induction ) : Modified APO : Arm I , methotrexate administer day 1 course 1 , 3 , 5 ( day 1-5 patient CNS disease ) . Courses repeat every 21 day total 15 course . Patients CNS disease begin radiotherapy Regimen B week 2 maintenance . Regimen A : Patients begin radiotherapy ( 5 day week 4.5 week ) residual tumor day 1 maintenance . Regimen B : Patients receive whole brain irradiation ( 5 day week 3.1 week ) begin day 1 maintenance . Patients follow monthly 6 month , every 3 month 18 month , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 242 patient accrue study approximately 5.4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated large cell lymphoma , include follow histologic designation : Rappaport classification Diffuse histiocytic Mixed lymphocytichistiocytic Working Formulation classification Diffuse large cell , cleave and/or noncleaved Immunoblastic Diffuse , mix small large cell LukesCollins classification Diffuse large cleave Diffuse large noncleaved Immunoblastic T B cell True histiocytic Updated Kiel classification Cytocentric large cell Centroblasticcentrocytic Tzone Lymphoepithelioid cell ( Lennert 's ) Immunoblastic T B cell Large cell anaplastic Pleomorphic Centroblasticcentrocytic , diffuse Malignant histiocytosis Murphy stage III/IV HIVassociated lymphoma eligible Any degree bone marrow involvement eligible CNS disease eligible ( patient randomize ) PATIENT CHARACTERISTICS : Age : Under 22 Performance status : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>